GlaxoSmithKline CFO Simon Dingemans has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
Counterfeit drugs manufactured in China and sold in the U.S. have become a plague on the industry, but China also suffers from counterfeits being sold to its own citizens. According to CRIEnglish ,...
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
Teva CEO Jeremy Levin thinks his company and China are a match made in heaven. The Israeli generics giant is, after all, adept at making and selling cheap drugs, which the fast-growing Chinese market needs. And Teva has a strong portfolio of respiratory treatments--perfect for a country beset by air pollution.
China is in the middle of one of its 5-year economic plans, and it's got big plans for biopharma. China Daily reports that the sales revenue for the industry came close to $29 billion last year, up a whopping 18%. And the government is feeding about a half billion dollars in annual government support to keep the growth going at the same torrid pace.
Mindray Medical, China's largest devicemaker, has been working to differentiate its business, and the effort paid off in the first quarter as the company's swelling diagnostics segment led the way to 10.5% revenue growth.
The foundation of Sagent's model is in partnerships, but drug shortages and industry consolidation are changing the nature of the business and the U.S. company decided it wanted complete control of the $50 million plant, its first foray into owning a facility.
A scandal over toxic drug capsules in China last year brought more unwanted attention to the gap between the country's place in the pharma ingredient world and the ability of its regulators to keep things on the up-and-up.
The Japanese drugmaker will use the plant to tap growing demand in that country, as well as an export base for other emerging markets in Asia.